Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
ln Vitro |
P2X2/3Rs, P2X2Rs, P2X4Rs, or P2X7Rs are all slightly inhibited by aurine tricarboxylic acid[1]. In a concentration-dependent manner, auricin tricarboxylic acid suppresses the current of ATP activation [1]. via controlling the action of calcineurin [2]. Aurin tricarboxylic acid suppresses TWEAK-Fn14 in a weak manner. In GBM cells, aurin tricarboxylic acid (10 μM; 0.5-2 hours) suppresses NF-κB, Akt, and Src phosphorylation mediated by TWEAK-Fn14 [4]. Aurin tricarboxylic acid inhibits TWEAK and stimulates gold tricarboxylic acid (compound 8), which can prevent exogenous siRNA from being loaded by RISC but cannot control endogenous let-7 loading on AGO2 in cultivated cells [4].
|
---|---|
Cell Assay |
Western Blot analysis [4]
Cell Types: T98G, A172, GBM44 glioma cells Tested Concentrations: 10 μM Incubation Duration: 0.5 hrs (hours), 1 hour, 2 hrs (hours) Experimental Results: Abolition of the activation of TWEAK downstream signals, including phospholipids of the NF-κB family 6]. members p65, Akt, and Src in all three GBM cell lines. |
References |
|
Additional Infomation |
Aurintricarboxylic acid is a member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'. It has a role as a histological dye, an insulin-like growth factor receptor 1 antagonist and a fluorochrome. It is a monohydroxybenzoic acid, a member of quinomethanes and a tricarboxylic acid. It is a conjugate acid of an aurintricarboxylate.
A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues. |
Molecular Formula |
C22H14O9
|
---|---|
Molecular Weight |
422.35
|
Exact Mass |
422.063
|
CAS # |
4431-00-9
|
Related CAS # |
13186-45-3 (tri-hydrochloride salt);569-58-4 (tri-ammonium salt);63451-31-0 (calcium (2:3) salt);93480-02-5 (calcium (1:3) salt)
|
PubChem CID |
2259
|
Appearance |
Brown to black solid powder
|
Density |
1.6±0.1 g/cm3
|
Boiling Point |
759.6±60.0 °C at 760 mmHg
|
Melting Point |
300 °C(lit.)
|
Flash Point |
427.1±29.4 °C
|
Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
Index of Refraction |
1.751
|
LogP |
4.09
|
Hydrogen Bond Donor Count |
5
|
Hydrogen Bond Acceptor Count |
9
|
Rotatable Bond Count |
5
|
Heavy Atom Count |
31
|
Complexity |
841
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
GIXWDMTZECRIJT-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H14O9/c23-16-4-1-10(7-13(16)20(26)27)19(11-2-5-17(24)14(8-11)21(28)29)12-3-6-18(25)15(9-12)22(30)31/h1-9,23-24H,(H,26,27)(H,28,29)(H,30,31)
|
Chemical Name |
5-[(3-Carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-2-hydroxybenzoic acid
|
Synonyms |
Aurintricarboxylic acid ATA NSC 4056 NSC4056 NSC-4056
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~295.97 mM)
NH4OH : 10 mg/mL (~23.68 mM) H2O : < 0.1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3677 mL | 11.8385 mL | 23.6770 mL | |
5 mM | 0.4735 mL | 2.3677 mL | 4.7354 mL | |
10 mM | 0.2368 mL | 1.1839 mL | 2.3677 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.